Chemistry:MK-608

From HandWiki
Short description: Chemical compound
MK-608
MK-608.svg
Clinical data
Other names7-Deaza-2’-C-methyladenosine; 7DMA
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC12H16N4O4
Molar mass280.284 g·mol−1
3D model (JSmol)

MK-608 (7-deaza-2’-C-methyladenosine, 7DMA) is an antiviral drug, an adenosine analog (a type of nucleoside analog). It was originally developed by Merck & Co. as a treatment for hepatitis C, but despite promising results in animal studies,[1][2] it was ultimately unsuccessful in clinical trials.[3] Subsequently it has been widely used in antiviral research and has shown activity against a range of viruses, including Dengue fever,[4] tick-borne encephalitis virus,[5] poliovirus,[6][7] and most recently Zika virus,[8][9] in both in vitro and animal models. Since it has already failed in human clinical trials previously, it is unlikely MK-608 itself will be developed as an antiviral medication, but the continuing lack of treatment options for these emerging viral diseases means that much research continues using MK-608 and related antiviral drugs.[10]

See also

References

  1. "Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees". Antimicrobial Agents and Chemotherapy 53 (3): 926–34. March 2009. doi:10.1128/AAC.01032-08. PMID 19075052. 
  2. "Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents". Antimicrobial Agents and Chemotherapy 55 (2): 937–9. February 2011. doi:10.1128/AAC.00990-10. PMID 21115793. 
  3. "Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides". PLOS Pathogens 8 (11): e1003030. 2012. doi:10.1371/journal.ppat.1003030. PMID 23166498. 
  4. "A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs". The Journal of Infectious Diseases 195 (5): 665–74. March 2007. doi:10.1086/511310. PMID 17262707. 
  5. "Nucleoside inhibitors of tick-borne encephalitis virus". Antimicrobial Agents and Chemotherapy 59 (9): 5483–93. September 2015. doi:10.1128/AAC.00807-15. PMID 26124166. 
  6. "2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus". Antiviral Research 73 (3): 161–8. March 2007. doi:10.1016/j.antiviral.2006.09.007. PMID 17055073. 
  7. "Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses". Journal of Medicinal Chemistry 53 (22): 7958–66. November 2010. doi:10.1021/jm100593s. PMID 20964406. 
  8. "Nucleoside Inhibitors of Zika Virus". The Journal of Infectious Diseases 214 (5): 707–11. September 2016. doi:10.1093/infdis/jiw226. PMID 27234417. 
  9. "The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model". PLOS Neglected Tropical Diseases 10 (5): e0004695. May 2016. doi:10.1371/journal.pntd.0004695. PMID 27163257. 
  10. "Antiviral properties of deazaadenine nucleoside derivatives". Current Medicinal Chemistry 13 (29): 3529–52. 2006. doi:10.2174/092986706779026228. PMID 17168721.